ArticleFrontiers in medicine2025
Case Report: Difficulties in diagnosis of myeloid sarcoma of the breast by core needle biopsy.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Myeloid sarcoma (MS) is a rare neoplasm that arises from myeloid blasts outside the bone marrow. Diagnosing and treating MS in the breast can be challenging due to its rarity in this location. Clinicians should consider MS when a breast mass is detected to implement appropriate treatment and avoid unnecessary surgery. Case demonstration: A 25-year-old female with a 2-year history of acute myeloid leukemia and a 1-year history of hematopoietic stem cell transplantation was admitted due to bilateral breast masses present for 1 month. Breast MRI plain scan + enhancement revealed bilateral breast masses with irregular shapes, irregular borders, and significant enhancement, suggesting a malignant tumor. A bilateral breast biopsy was performed, and the pathological diagnosis confirmed MS involving the breast. Following the diagnosis, local radiotherapy was performed, and no recurrence was observed during the 1-month follow-up. Conclusion: The clinical manifestations of MS in the breast are typically nonspecific, and its imaging features resemble those of breast cancer or other malignant tumors. Therefore, diagnosing primary MS of the breast without a history of leukemia is challenging, and the final diagnosis requires a histopathological biopsy. For patients with a history of AML, imaging should be regularly reviewed for early detection, diagnosis, and treatment to improve prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.